Xuebin Qin, MD, PhD
Professor of Medicine
Tulane National Primate Research Center
Dr. Xuebin Qin’s research focuses on defining the role of innate immunity including complement system and monocyte activation in the pathogenesis of human diseases, such as HIV infection, HIV-associated cardiovascular diseases, and on developing a novel cell ablation research tool for broad scientific applications. He has extensive expertise in immunology, monocyte & macrophage biology, complement, HIV-1 therapy, atherosclerosis, and cancer biology. One of Dr. Qin’s research focuses has been to identify novel approach targeting complement system for HIV-1 therapy. Another portion of his research is to investigate HIV-associated cardiovascular diseases, such as atherosclerosis. His major contributions to the fields include: 1) generation a novel and potent anti-MAC regulator CD59 inhibitor, a potential therapeutic candidate for control HIV-1 infections. 2) generation of the novel mouse model for HIV-associated atherosclerossi, 3) establishment of the causative role of MAC in atherosclerosis, 4) documentation of the inhibition of MAC with a targeted complement inhibitor as a potential novel approach for the treatment of atherosclerosis-associated complications, and 5) generation of a human CD59 mediated novel cell ablation for dissecting immune cell functionality and differentiation.